New drug cocktail targets rare, aggressive melanoma
NCT ID NCT06424626
First seen Jul 06, 2026 · Last updated Jul 14, 2026 · Updated 3 times
Summary
This phase 1 trial tests two experimental drug combinations—AK104 or AK112 plus axitinib—in people with metastatic mucosal melanoma, a rare and hard-to-treat skin cancer. The study aims to find a safe dose and see whether the combinations shrink tumors. Participants receive the drugs intravenously every three weeks along with daily axitinib pills.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Cadonilimab (AK104) or Ivonescimab (AK112) plus Axitinib
- What this could lead to
- If successful, this could point toward a new treatment option for metastatic mucosal melanoma, a rare and aggressive skin cancer.
- What could go wrong
- This is an early phase 1 trial with a small number of participants, so the combinations may prove unsafe or ineffective. Side effects from the drugs are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital
Beijing, 100142, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer reveal whether immunotherapy is working?
- Can a new nucleotide analogue boost cancer treatment?
- Can a new drug ST316 shrink Hard-to-Treat tumors?
- Can a single tracer light up cancer's first stop? a trial puts a hybrid dye-and-radioactive marker to the test.
- Botox before the knife: could a Pre-Surgery injection lead to Better-Looking scars?
- Could a lighter immunotherapy schedule keep advanced cancers in check?